In recent years, five other drugs have been approved to treat gMG, including three complement inhibitors -- eculizumab (Soliris), ravulizumab (Ultomiris), and zilucoplan (Zilbrysq) – and two neonatal ...
BridgeBio Oncology Therapeutics (BBOT) targets KRAS and PI3Ka malignancies with next-generation small molecule therapeutics, ...
Amgen’s (AMGN) blinatumomab was granted FDA orphan designation as a treatment of acute lymphoblastic leukemia, according to a post to the agency’s ...
The Muscular Dystrophy Association (MDA) recognizes the U.S. Food and Drug Administration (FDA) approval of Amgen’s UPLIZNA ® (inebilizumab-cdon) for the treatment of generalized myasthenia gravis ...
The larger risk reductions were not explained by changes in LDL cholesterol, suggesting something else is at play.
Amgen secures FDA approval for Uplinza in generalized myasthenia gravis, giving antibody-positive adults a targeted treatment option supported by Phase 3 data.
Amid a swell of regulatory successes in the myasthenia gravis arena this decade, Amgen is wading into the fray with a new ...
Generalized myasthenia gravis is Uplizna’s second new indication this year, after the FDA cleared the anti-CD19 antibody for ...
The Muscular Dystrophy Association (MDA) recognizes the U.S. Food and Drug Administration (FDA) approval of Amgen's UPLIZNA(R) (inebilizumab-cdon) for the treatment of generalized myasthenia gravis ...
Drug development in biotechnology takes time. A lot of time. On average, it takes 10 to 15 years to take a medicine from ...
After three decades spent rising through the ranks of sales and marketing teams at major pharmas, Chris Boulton is taking the ...
Using a kind of novel linker technology, the startup is developing versions of incretin and non-incretin therapies that can ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback